Fasting-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration to Reverse Diabetes

Graphical Abstract

Highlights
- Fasting mimicking diet induces prenatal-development gene expression in adult pancreas
- FMD promotes Ngn3 expression to generate insulin-producing β cells
- Cycles of FMD reverse β-cell failure and rescue mice from T1D and T2D
- Inhibition of PKA or mTOR promotes Ngn3-driven β-cell regeneration in human T1D islets

Authors
Chia-Wei Cheng, Valentina Villani, Roberta Buono, ..., Julie B. Sneddon, Laura Perin, Valter D. Longo

Correspondence
vlongo@usc.edu

In Brief
A periodic short-term diet that mimics fasting modulates β-cell regeneration and promotes insulin secretion and glucose homeostasis with potential to treat both type 1 and type 2 diabetes.

Cheng et al., 2017, Cell 168, 775–788
February 23, 2017 © 2017 Elsevier Inc.
http://dx.doi.org/10.1016/j.cell.2017.01.040
Fasting-Mimicking Diet Promotes Ngn3-Driven β-Cell Regeneration to Reverse Diabetes

Chia-Wei Cheng,1,6,7 Valentina Villani,2,7 Roberta Buono,1,6,7 Min Wei,1 Sanjeev Kumar,4 Omer H. Yilmaz,6 Pinchas Cohen,1 Julie B. Sneddon,3 Laura Perin,2 and Valter D. Longo1,4,5,8,*

1Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, CA 90089-0191, USA
2GOFARR Laboratory for Organ Regenerative Research and Cell Therapeutics, Children’s Hospital Los Angeles, Division of Urology, Saban Research Institute, University of Southern California, Los Angeles, Los Angeles, CA 90027, USA
3Diabetes Center, University of Southern California, 513 Parnassus Avenue, San Francisco, CA 94143
4Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC, Keck School of Medicine, University of Southern California, Los Angeles, CA 90027, USA
5IFOM FIRC Institute of Molecular Oncology, Via Adamello 16, Milan 20139, Italy
6Koch Institute at MIT, 500 Main Street, Cambridge, MA 02139, USA
7Co-first author
8Lead Contact
*Correspondence: vlongo@usc.edu
http://dx.doi.org/10.1016/j.cell.2017.01.040

SUMMARY

Stem-cell-based therapies can potentially reverse organ dysfunction and diseases, but the removal of impaired tissue and activation of a program leading to organ regeneration pose major challenges. In mice, a 4-day fasting mimicking diet (FMD) induces a stepwise expression of Sox17 and Pdx-1, followed by Ngn3-driven generation of insulin-producing β cells, resembling that observed during pancreatic development. FMD cycles restore insulin secretion and glucose homeostasis in both type 2 and type 1 diabetes mouse models. In human type 1 diabetes pancreatic islets, fasting conditions reduce PKA and mTOR activity and induce Sox2 and Ngn3 expression and insulin production. The effects of the FMD are reversed by IGF-1 treatment and recapitulated by PKA and mTOR inhibition. These results indicate that a FMD promotes the reprogramming of pancreatic cells to restore insulin generation in islets from T1D patients and reverse both T1D and T2D phenotypes in mouse models.

INTRODUCTION

The ability of animals to survive food deprivation is an adaptive response accompanied by the atrophy of many tissues and organs to minimize energy expenditure. This atrophy and its reversal following the return to a normal diet involve stem-cell-based regeneration in the hematopoietic and nervous systems (Brandhorst et al., 2015; Cheng et al., 2014). However, whether prolonged fasting and refeeding can also cause pancreatic regeneration and/or cellular reprogramming leading to functional lineage development is unknown. β cells residing in pancreatic islets are among the most sensitive to nutrient availability. Whereas type 1 and type 2 diabetes (T1D and T2D) are characterized by β-cell dedifferentiation and trans-differentiation (Cnop et al., 2005; Dor and Glaser, 2013; Talchai et al., 2012; Wang et al., 2014), β-cell reprogramming, proliferation and/or stepwise re-differentiation from pluripotent cells are proposed as therapeutic interventions (Baeyens et al., 2014; Chera et al., 2014; Maehl et al., 2009; Pagliuca et al., 2014; Sneddon et al., 2012; Zhou et al., 2008; Ben-Othman et al., 2017; Li et al., 2017), suggesting that lineage conversion is critical in both diabetes pathogenesis and therapy (Weir et al., 2013).

Although dietary intervention with the potential to ameliorate insulin resistance and type II diabetes has been studied extensively for decades, whether this has the potential to promote a lineage-reprogramming reminiscent of that achieved by iPSCs-based engineering remains unknown. We previously showed that cycles of prolonged fasting (2–3 days) can protect mice and humans from toxicity associated with chemotherapy and can promote hematopoietic stem-cell-dependent regeneration (Cheng et al., 2014; Laviano and Rossi Panelli, 2012; Raffagello et al., 2008). In consideration of the challenges and side effects associated with prolonged fasting in humans, we developed a low-calorie, low-protein and low-carbohydrate but high-fat 4-day fasting mimicking diet (FMD) that causes changes in the levels of specific growth factors, glucose, and ketone bodies similar to those caused by water-only fasting (Brandhorst et al., 2015) (see also Figure S1 for metabolic cage studies). Here, we examine whether cycles of the FMD are able to promote the generation of insulin-producing β cells and investigate the mechanisms responsible for these effects.

RESULTS

Cycles of a FMD Rescue Mice from Late-Stage T2D

As a consequence of insulin resistance, the decrease in the number of functional insulin-producing β cells contributes to the pathophysiology of T2D by eventually leading to insulin deficiency (Cnop et al., 2005; Dor and Glaser, 2013). Previously, we...
showed that a 4-day fasting mimicking diet (FMD) could induce metabolic changes similar to those caused by prolonged fasting and could reduce insulin and glucose levels while increasing ketone bodies and igfbp1 (Brandhorst et al., 2015; Figure S1). Although the role of periodic fasting and fasting mimicking diets on insulin secretion is unknown, the effects of intermittent fasting and chronic calorie restrictions (CR) on insulin sensitivity have been previously reported (Barnosky et al., 2014). Here, our focus is on the putative effects of the FMD in promoting β-cell regeneration, although we have also investigated the effects of the FMD on insulin resistance.

Given that β cells replicate at an extremely low rate in the adult pancreas (Meier et al., 2008; Teta et al., 2005) and that β-cell neogenesis occurs rarely (Xiao et al., 2013), depletion of β cells and the consequent loss of insulin secretion during late-stage diabetes have often been considered conditions whose reversals require islet and stem cell transplantation (Fiorina et al., 2008; Kroon et al., 2008; Milanesi et al., 2012; Pypeleers et al., 2002; Villani et al., 2014). To determine whether the FMD could affect the β-cell deficiency associated with T2D, we studied its effect on mice with a point mutation in the leptin receptor gene (Lepr<sup>db/db</sup>), which causes insulin resistance in the early stages and failure of β-cell function in the late stages. As reported by others, db/db mice developed hyperglycemia at 10 weeks of age, which we refer to as baseline (BL) (Figure 1A). The insulin levels first increased to compensate for insulin resistance but drastically declined after 2 weeks of severe hyperglycemia (Figures 1B and 1C) (Arakawa et al., 2001). As a result, db/db mice began to die at around 4 months of age. We attempted to reverse these late-stage T2D phenotypes by treating 12-week-old mice (14 days after the hyperglycemia stabilized, baseline) with weekly cycles of the 4-day FMD (Figure 1A). FMD cycles caused a major reduction and return to nearly normal levels of blood glucose in db/db mice by day 60 (Figure 1B). The FMD cycles also reversed the decline in insulin secretion at day 30 and improved plasma insulin levels at day 90 (Figure 1C). A homeostasis model assessment (HOMA) was performed to estimate steady-state β-cell function (%B) and insulin sensitivity (%S), as previously described (Hsu et al., 2013; Matthews et al., 1985). The results indicate that the reversal of hyperglycemia was mainly caused by an induction of steady-state β-cell function (%B) (Figure 1D). Nevertheless, mice receiving the FMD showed improved glucose tolerance and insulin tolerance compared to the ad libitum (AL) fed controls (Figure 1E). Notably, although db/db mice on the FMD diet gained less weight compared to those on the regular diet, they maintained a weight that was ~22% higher than that of their healthy wild-type (WT) littermates during the entire experiment (Figure S2C). Altogether, these results indicate that FMD cycles rescued mice from late-stage T2D by restoring insulin secretion and reducing insulin resistance, leading to a major improvement in survival (Figure 1F, *p < 0.05, log-rank test for trend).

**Cycles of FMD Reverse β-Cell Failure in T2D**

Dedifferentiation of β cells, which results in increased non-hormone-producing cells within pancreatic islets, is a feature of diabetic β-cell failure (Dor and Glaser, 2013; Kim-Muller et al., 2014; Talchai et al., 2012). Similar to what was previously reported by others, we found an increase in cells producing neither insulin nor glucagon (i.e., non-α/β) and a decrease in β-cell number in pancreatic islets of late-stage T2D mice, but not in age-matched WT controls (Figures 1G and S2, db/db BL compared to WT/AL). We also found that β-cell proliferation was low in the late stage of the disease (Figure 1H, AL day 60 compared to BL). Whereas db/ db mice fed ad libitum (db/db:AL) showed a 60%–80% reduction in β-cell count at day 60, db/db mice receiving FMD cycles (db/db:FMD) displayed a major improvement in the number and proliferation of insulin-generating β cells (comparing db/db BL, Figures 1G-1I). Pancreatic islets collected from db/db mice treated with FMD cycles (day 60) displayed increased glucose-stimulated insulin secretion (GSIS), compared to that of islets from db/db:AL mice (Figure 1J). We also determined that a longer exposure time (time point 120) was necessary to distinguish between the functionality of islets from db/db:AL and db/db:FMD group mice (Figure 1J). Overall, these results suggest that, in addition to improving insulin sensitivity, FMD induced β-cell regeneration to reverse β-cell loss, which may alleviate late-stage T2D symptoms and mortality.

**Figure 1. FMD Cycles Promote β-Cell Regeneration and Reverse β-Cell Failure in T2D**

(A) Experimental scheme to determine effects of the periodic FMD on T2D in the leptin-receptor-deficient (Lepr<sup>db/db</sup>) mice. Mice were monitored for hyperglycemia and insulinemia from 10 weeks (baseline, BL) to 12 weeks and were then assigned to the dietary groups. Each FMD cycle entails 4-day FMD and up to 10 days of refeeding (RF). During refeeding, mice received a regular chow identical to that given prior to the FMD and that given to the ad libitum (AL) controls.

(B) Plasma glucose levels and (C) plasma insulin levels; vertical dashed lines indicate each cycle of the FMD, and horizontal lines indicate the range of glucose levels (mean ± SEM) in age-matched healthy wild-type littermates. Blood samples were collected at the last refeeding day/first day of the indicated cycles. Mice were fasted for 6 hr (morning fasting) for blood glucose measurements.

(D) Homeostatic model assessment (HOMA) of insulin resistance (IR) and steady-state β-cell function (%B) at indicated time points. HOMA-B = (20 × fasting insulin)/(fasting glucose – 3.5)/%.

(E) Glucose tolerance test and insulin tolerance test at day 60.

(F) Survival curve. Mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.005, two-way ANOVA.

(G) Proportion of β cells per islet. n ≥ 6 mice per group, n ≥ 15 islets per sample.

(H) Proliferative proportion of β cells per islet.

(I) Immunostaining of pancreatic sections from Lepr<sup>db/db</sup> mice and their wild-type littermates at the indicated time points. Arrow in the 8×-enlarged example image indicates a typical proliferative β cell (PCNA+Insulin+). Scale bar, 50 μm.

(J) Representative images for size-matched islets isolated from AL-dbodb and FMD-dbdb mice and results of glucose-stimulated insulin secretion (GSIS) test in islets isolated from Lepr<sup>db/db</sup> mice on FMD or fed ad libitum. Scale bar, 50 μm.

Mice are of the C57BL/6J background of the age indicated. In (A), mice received no additional treatments other than the indicated diet.
**A**

High-dose STZ

![Diagram](image)

**B**

![Graph](image)

**C**

![Graph](image)

**D**

IPGTT

![Graph](image)

**E**

*β-cell regeneration* - *β-cell insults*

![Bar Chart](image)

**F**

Proliferative β cells

![Graph](image)

**G**

β cells

![Graph](image)

**H**

UNTREATED (CTRL) STZ BL (d5) STZ (d50) STZ + FMD (d50)

![Images](image)

*(legend on next page)*
FMD Cycles Restore Insulin-Dependent Glucose Homeostasis in STZ-Induced T1D

To examine further the role of FMD cycles in stimulating β-cell regeneration, we applied FMD cycles on a T1D model in which high-dose streptozotocin (STZ) treatment causes the depletion of insulin-secreting β cells (Wu and Huan, 2008; Yin et al., 2006). Starting 5 days after STZ treatment, which we refer to as baseline (STZ BL), hyperglycemia (>300 mg/dl) was observed in both mice fed AL and those subjected to multiple cycles of the 4-day FMD every 7 days (4 days of FMD followed by 3 days of re-feeding, every 7 days per cycle) (Figures 2A and 2B). Levels of blood glucose continued to increase in STZ-treated mice receiving the AL diet and reached levels above 450 mg/dl at both days 30 and 50. On the other hand, in mice receiving FMD cycles, hyperglycemia and insulin deficiency were both significantly alleviated on day 30 (Figure 2B, sample size indicated in parentheses). Remarkably, the levels of these physiological parameters returned to a nearly normal range at days 50–60 after the FMD cycles (Figures 2B and 2C, sample size indicated in parentheses). Intraportal glucose tolerance tests (IPGTTs) at day 50 confirmed that STZ-treated mice undergoing the FMD cycles have improved capacity to clear exogenous blood glucose (STZ+ FMD), compared to mice on the regular chow (STZ) (Figure 2D).

Levels of certain circulating cytokines have been used as indicators to determine islet pathological status in patients with recent-onset T1D (Baeyens et al., 2014; Grunnet et al., 2009; Lebastchi and Herold, 2012). We performed a 23-plex immunoassay to determine the effects of the FMD on inflammatory markers. We found that FMD cycles not only suppressed the circulating cytokines associated with β-cell damage (e.g., TNF-α and IL-12), but also increased circulating cytokines associated with β-cell regeneration (e.g., IL-2 and IL-10) (Figure 2E, day 30) (Dirice et al., 2014; Rabinovitch, 1998; Zhernakova et al., 2006).

Taken together, these results indicate that FMD cycles reduce inflammation and promote changes in the levels of cytokines and other proteins, which may be beneficial for the restoration of insulin secretion and the reversal of hyperglycemia.

FMD Cycles Reverse STZ-Induced β-Cell Depletion

The characterization of pancreatic islet cells indicates a strong association between restored glucose homeostasis and the replenishment of pancreatic β cells in animals undergoing FMD cycles. STZ treatments resulted in an increase of non-α/β cells (Figure S3) and an ~85% depletion of insulin-secreting β cells (Figure 2F, STZ BL). The transient increase of non-α/β cells was reversed by day 30 in both groups (Figures 2D and 2E). Mice receiving weekly cycles of the FMD showed a major increase in proliferative β cells followed by a return to a nearly normal level of insulin-generating β cells by d50 (Figures 2F–2H). In contrast, mice that received ad libitum access to regular chow remained depleted of β cells for >50 days (Figures 2F and 2H). Overall, the increase of non-α/β prior to β-cell proliferation raises the possibility that weekly cycle of the FMD might mediate the fate conversion of non-α/β cells to β cells to reverse the STZ-induced β-cell depletion, although other scenarios are possible.

FMD and Post-FMD Re-feeding Promote β-Cell Regeneration in Non-diabetic Mice

We investigated whether and how the FMD and the post-FMD re-feeding period could regulate the cell populations within the islets to promote β-cell regeneration independently of diabetes, with a focus on the non-α/β cells and proliferative β cells. To characterize cellular and hormonal changes, pancreatic samples and peripheral blood of wild-type C57Bl6 mice fed with the FMD for 4 days were collected before the diet (BL), at the end of the diet (day 4), and 1 or 3 days after mice returned to the normal diet (RF1d or RF3d). The FMD caused a trend of decrease in the number and size of pancreatic islets (Figure 3A) and reduced the proportion of β cells by 35% (Figures 3B and 3C; see also Figure S4 for absolute numbers). These effects were reversed within 3 days of re-feeding (Figures 3A and 3C). Non-α/β cells began to proliferate at the end of the FMD, and this proliferation persisted until 1 day after re-feeding (RF1d), leading to a 2.5-fold increase in non-α/β cells (proportion per islet) at RF1d (Figure S4). By RF3d, the number of non-α/β cells had dropped and that of β cells returned to basal levels (BL), although β cells remained in a much more proliferative state in the FMD group (Figure 3B and 3C). The expression of the proliferation marker PCNA was elevated in β cells, but not α cells, after re-feeding post FMD (Figures 3B and 3C and S4). Despite the number of α cells per islet remaining the same, the transitional α-to-β or β-to-α cells that co-express both α (i.e., glucagon) and β cell (i.e., Pdx-1 or insulin) markers were increased in mice that received the FMD (Figure 3D). In summary, the FMD promotes a decrease in the numbers of differentiated or committed cells, followed by the induction of transitional cells and major increases in the proliferation and number of insulin-generating β cells (Figure 3E).

Figure 2. FMD Cycles Reverse STZ-Induced β-Cell Depletion and Restore Glucose Homeostasis

(A) Experimental scheme of the periodic FMD’s effects on STZ-induced T1D. Baseline measurements (BL) were performed at day 5 after STZ treatment.

(B) Fasting glucose levels and (C) plasma insulin levels during and 55 days after the FMD cycles (d5 to d35). Vertical dashed lines indicate each cycle of FMD; horizontal lines (125 ± 12 mg/dl) indicate levels of blood glucose in the naïve control mice.

(D) Glucose tolerance test at d30.

(E) Cytokine profile of mice treated with STZ or STZ+FMD at d30, compared to that in naïve controls. Pancreatic samples collected at indicated time points were analyzed for:

(F) PCNA+ proliferating β cells.

(G) Proportion of insulin-producing β cells per islet and (H) representative micrographs with immunostaining of insulin, glucagon, and DAPI on pancreas sections of mice treated with STZ or STZ + FMD at the indicated time points. Scale bar, 50 μm.

Mice of the C57Bl6/6j background, age 3–6 months, received STZ treatments (150 mg/kg) as indicated in (A). For (B–G), each point represents the mean ± SEM, and sample size (n) is indicated in parentheses. (F and G) *p < 0.05, **p < 0.01, ***p < 0.005, one-way ANOVA. Ctrl, STZ-untreated control; STZ BL, baseline level of STZ treated mice at day 5. n ≥ 6 mice per group per time point, n ≥ 15 islets per mouse.
Figure 3. FMD and Post-FMD Refeeding Promote β-Cell Proliferation and Regeneration

(A) Size and number of pancreatic islets per pancreatic section.
(B) Proportion of PCNA+ proliferating β cells and of total β cells per islet.
(C) Representative images of pancreatic islets with insulin, glucagon, and PCNA immuno-staining. Scale bar, 50 μm.

(legend continued on next page)
**FMD Promotes a Gene Expression Profile in Adult Mice Similar to that Observed during Embryonic and Fetal Development**

To identify the genes that may mediate the FMD-induced pancreatic regeneration, we measured gene expression in pancreatic islets at the end of the FMD and post-FMD refeeding. At both time points, we observed a transient upregulation of Foxo1 (6.9-fold at FMD, 5.3-fold at RF1d, \( p < 0.05 \) comparing to AL) and of a set of genes that have been previously identified as dual regulators for both fat metabolism and fate determination in mammalian cells (Cook et al., 2015; Haeusler et al., 2014; Johnson et al., 2004; Kim-Muller et al., 2014; Mu et al., 2006; Stanger, 2008; Talchai et al., 2012; Talchai and Accili, 2015; Tonne et al., 2013) (Figure 4A), in agreement with the metabolic changes found in mice receiving the FMD (Figure S1). We further examined whether the metabolic reprogramming caused by the FMD affects lineage determination. In Figure 4B, the expression of lineage markers was determined by the mRNA expression of purified FMD (Figure S1B), in agreement with the metabolic changes found in mice receiving the FMD (Figure S1). The number of Ngn3+ cells was increased both inside and outside of the islets during the FMD and re-feeding (Figure 4D).

These results suggest that, as a result of the FMD and re-feeding cycle, the pancreatic islets contain an elevated number of cells with features of progenitor cells, which may differentiate and generate insulin-producing cells.

**FMD Induces Ngn3 Expression to Generate Insulin-Producing \( \beta \) Cells**

Ngn3+ cells within the pancreatic islets have been previously described as progenitor cells able to generate all lineages of endocrine cells, including the insulin-producing \( \beta \) cells, although the role of Ngn3 in adult \( \beta \)-cell regeneration remains unclear (Baeyens et al., 2014; Van de Casteele et al., 2013; Xu et al., 2008). To investigate whether the FMD causes de novo expression of Ngn3 and whether Ngn3+ cells may contribute to FMD-induced \( \beta \)-cell regeneration, we generated Ngn3-CreER;tdTomato\(^\text{LSL-reporter}\) mice to trace the lineage of putative Ngn3-expressing cells and their progeny in the adult mice treated with the FMD (Figure 5A). To initiate the loxp\(^\text{P}\) recombination for lineage tracing, low-dose tamoxifen injections (2 mg per day for 3 days) induced the recombination (maximized at 48 hr and minimized within a week) were given to mice before or after the FMD and to mice fed ad libitum (AL control) (Figure 5A). Tissue collection time points are relative to the time of injection and to that of FMD treatments (Figure 5A). Results indicate that the FMD induces the expansion of the Ngn3-derived lineages (Figure 5B and 5C). Characterization of tdTomato+ cells by immunostaining indicates that tdTomato+ cells contributed 50.8% ± 8.3% of the overall \( \beta \)-cell pool following the FMD (Figure 5C, group C).

To confirm the contribution of FMD-induced Ngn3 lineages in reconstituting insulin-secreting \( \beta \) cells, we generated another mouse model (Ngn3-CreER/LSL-R26\(^\text{R\text{DTAGA}}\)) and performed lineage-ablation experiments in both wild-type non-diabetic mice and Ngn3-/- and insulin-secreting \( \beta \) cells.
and STZ-treated mice (Figure 5D). The results indicate that ablation of Ngn3+ lineage reverses FMD-induced ß-cell regeneration and its effects on fasting glucose levels (Figures 5E and 5F and S5) and glucose clearance capacities (IPGTT assay) in STZ-treated diabetic mice (Figure 5G), confirming that the FMD-induced ß-cell regeneration is Ngn3 dependent and suggesting a critical role for this in glucose homeostasis.

Fasting Conditions or Inhibition of Nutrient-Signaling Pathways Promote Ngn3 Expression and Insulin Production in Human Pancreatic Cells

In both mouse and humans, Ngn3 expression occurs right before and during endocrine cell generation. Ngn3 mRNA expression in the developing mouse pancreas peaks around E15.5, which is roughly equivalent to week 7–8 (Carnegie stages 21–22) in
human development. Expression of Ngn3 in adult mouse islets, although rare, has been demonstrated by rigorous lineage reporter analysis (Wang et al., 2009). In agreement with results from others, our data (Figures 5 and S5) indicate that Ngn3+ cells in adult pancreas islets are important for β-cell regeneration in mice. On the other hand, the role of Ngn3 in human islet...
development and β-cell regeneration in adulthood remains poorly understood (McKnight et al., 2010).

To investigate how the fasting mimicking conditions affect Ngn3 expression and β-cell function in human pancreatic cells, we performed ex vivo experiments using primary human pancreatic islets (Figure 6A). Briefly, the pancreatic islets from healthy and T1D subjects (HI and T1DI, respectively) were cultured according to the manufacturer’s instructions. The cultured islets were then treated with serum from subjects enrolled in a clinical trial testing the effects of a low-protein and low-calorie FMD lasting 5 days (NCT02158897). Serum samples were collected at baseline and at day 5 of the fasting mimicking diet in five subjects. We then measured IGF-1, glucose, and ketone bodies and treated human pancreatic islets with the subject-derived serum (Figure 6B and Table S1). In both healthy islets and T1D islets exposed to the serum of FMD-treated subjects, we observed a trend for glucose-dependent induction in the expression of Sox2 and Ngn3 (Figure 6A).

We then applied the low-glucose and low-serum fasting mimicking medium (STS) to the cultured pancreatic islets and found that it significantly stimulated the secretion of insulin in both HI and T1DI (Figure 6C). We further investigated the expression of lineage-reprogramming markers, which we found to be upregulated in mice as a result of the FMD-treatment (i.e., Nanog, Sox17, Sox2, Ngn3, and Ins). The results indicate that the fasting mimicking conditions had strong effects in inducing the expression of Sox2, Ngn3, and insulin in human pancreatic islets from healthy (healthy islets, HI) and T1D subjects (T1D islets, T1DI) (Figures 6D–6F). In cells from normal human subjects, these effects were reversed by IGF-1 treatment (Figure 6G). Notably, in human T1D cells, IGF-1 reversed the increased insulin and Sox2 gene expression, but not that of Ngn3 expression caused by the STS medium (Figure 6G versus Figures 6D and 6E).

Future studies are warranted to further investigate the role of circulating IGF-1 in the expression of lineage-reprogramming markers and pancreatic islet cells regeneration in vivo.

In both healthy and T1D human islets, STS medium significantly reduced the activity of PKA, an effect reversed by IGF-1 treatment (Figure 6H). It also dampened the activity of mTOR, which is a key mediator of amino acid signaling (Figure 6I). To further investigate the role of these nutrient-sensing signaling pathways in regulating the expression of lineage markers (i.e., Sox2, Sox3, and Ngn3), we tested the role of the mTOR-S6K and PKA pathways, which function downstream of IGF-1, in the reprogramming of pancreatic cells. Human pancreatic islets cultured in standard medium were treated with rapamycin, which inhibits mTOR, and H89, which inhibits PKA. mTOR and PKA were implicated by our group and others in the regeneration of other cell types (Cheng et al., 2014; Yilmaz et al., 2012). We found that, in human islets from T1D subjects (T1DI), expression of the essential lineage markers Sox2 and Ngn3 was not induced by inhibition of either mTOR or PKA but was significantly induced when both mTOR and PKA were inhibited (Figures 6J and 6K).

Interestingly, the constitutive mTOR, but not PKA, activity is trending higher in HI compared to T1D1 cells (Figure 6J, lane 1 for both sets for mTOR activity and Figure 6H for PKA activity), which may explain the overall differences between HI and T1DI in Sox2 and Ngn3 expression shown in Figure 6J. Taken together, these results indicate that fasting cycles may be effective in promoting lineage reprogramming and insulin generation in pancreatic islet cells, in part by reducing IGF-1 and inhibiting both mTOR and PKA signaling. Pancreatic cells from T1D subjects displayed constitutively elevated activity of mTOR-S6K and PKA, which points to the potential for inhibitors of both pathways in the induction of Ngn3-mediated lineage reprogramming. These results raise the possibility that the effect of the FMD on pancreatic regeneration in T1D subjects could be mimicked or enhanced by pharmacological inhibition of these pathways.

DISCUSSION

During mouse development, at embryonic day E8.5, pancreatic progenitor cells co-express the SRY-related HMG-box transcription factor Sox17 and the homeodomain transcription factor Pdx1. These multipotent pancreatic progenitors are then converted into bipotent epithelial cells that generate duct cells or a transient population of endocrine precursor cells expressing the bHLH factor Neurogenin3 (Ngn3). Ngn3+ endocrine precursors give rise to all of the principal islet endocrine cells, including glucagon+ α cells and insulin+ β cells (Arnes et al., 2012). In mice, expression of Ngn3 in the developing pancreas is transient, detectable between E11.5 and E18 (Arnes et al., 2012). Whether developmental genes, including Sox17, Pdx-1, and Ngn3, could be activated to generate functional β cells in adults was previously unknown.

Both cell-based therapy and the use of cytokines and hormones that stimulate β-cell self-replication have the potential to restore insulin-producing β cells in diabetic patients (Dirice et al., 2014). However, despite some success with transplantation-based...
therapy, the short supply of donor pancreata plus the inefficient conversion of stem cells into specialized derivatives have represented obstacles for clinical application, suggesting that a successful β-cell regeneration might depend on the coordinated activation and re-programming of endogenous progenitors (Blum et al., 2014; Sneddon et al., 2012; Wang et al., 2009; Xiao et al., 2013). Recently, this in vivo lineage reprogramming or trans-differentiation has become an emerging strategy to regenerate β cells (Cohen and Melton, 2011; Heinrich et al., 2015; Abad et al., 2014; Sneddon et al., 2012; Wang et al., 2009; Xiao et al., 2015). The FMD appears to cause pancreatic islets to first increase β-cell number followed by its return to normal levels after re-feeding, suggesting an in vivo lineage reprogramming. We show that the severe hyperglycemia and insulinemia in both the late-stage Lepr<sup>db/db</sup> T2 and the STZ-treated T1 mouse diabetes models were associated with severe β-cell deficiency in pancreatic islets. Six to eight cycles of the FMD and re-feeding were required to restore the β-cell mass and insulin secretion function and to return the 6-hr-fasting blood glucose to nearly normal levels. In non-diabetic wild-type mice, the portion of β cells per islet, as well as the total number of β cells per pancreas, were reduced at the end of a 4-day FMD, but their normal level was completely restored within 3–5 days post re-feeding. Also, insulin and blood glucose levels were reduced by 70% or more at the end of the FMD period but returned to normal levels within 24–36 hr of re-feeding. Interestingly, in diabetic mice, the majority of cells residing in the islets expressed neither insulin nor glucagon (i.e., non-α/β). This phenotype was also found in non-diabetic wild-type mice during the FMD and was accompanied by an increase of other transitional cell types (i.e., Pdx1+/Glucagon+ cells and Insulin+/glucagon+) followed by significant β-cell regeneration upon re-feeding. This suggests that the FMD alters the gene expression profile that normally suppresses the generation of β cells. More importantly, these results suggest that dietary-induced lineage conversion occurring prior to the β-cell proliferation may play an important role in β-cell regeneration across the diabetic and non-diabetic mouse models. One possibility is that glucagon and insulin expression are transiently suppressed in α and β cells during the FMD, followed by lineage reprogramming in committed cells. Another possibility is that the FMD may cause cell death and then stimulate progenitor or other cells to regenerate β cells.

The FMD reversed the dedifferentiated expression profile for a number of genes associated with maturity-onset diabetes of the young (MODY) and regulated by Foxo1 (Kim-Muller et al., 2014). The FMD appears to cause pancreatic islets to first increase the expression of Foxo1 and its transcriptional targets, then induce transitionally the expression of the progenitor cell marker Ngn3 upon re-feeding, leading to β-cell regeneration. We conclude that, together with the changes in a wide range of cytokines associated with β-cell regeneration, FMD and post-FMD re-feeding generate the complex and highly coordinated conditions that promote the generation of stable insulin-producing β-cells to reverse severe β-cell depletion. The key changes priming pancreatic islet cells for regeneration during the FMD appear to be the reduction of IGF-1 levels and the consequent downregulation of PKA and mTor activity, in agreement with the role for these pathways in hematopoietic (Cheng et al., 2014) and intestinal stem-cell self-renewal (Yilmaz et al., 2012). It was proposed that transient de-differentiation of β cells may play a role in their in vivo dynamics (Kim-Muller et al., 2014; Weinberg et al., 2007). The capacity of these de-differentiated cells to re-differentiate fundamentally changes the therapeutic potential of existing cells in promoting β-cell regeneration and reversing T1D symptoms (Blum et al., 2014; Wang et al., 2014). Thus, our study provides an example of a potent and coordinated dietary regulation of cell-fate determination with the potential to serve as a therapeutic intervention to treat diabetes and other degenerative diseases. Our preliminary results from a pilot clinical trial also indicate that the use of periodic cycles of a prolonged FMD is feasible and ready to be tested in large randomized clinical trials for effects on both insulin resistance and pancreatic β-cell regeneration for the treatment of both T1D and T2D.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
  - Mouse models
  - Lineage tracing and Lineage ablation
  - Human pancreatic islets
  - Human subjects (FMD)
- **METHOD DETAILS**
  - Mouse fasting mimicking diet
  - Post-FMD refeeding
  - Blood glucose and insulin measurement
  - Intraperitoneal glucose tolerance testing (IPGTT) and insulin tolerance testing
  - Immunofluorescence Analysis
  - Pancreatic Islet isolation
  - Cell Lineage Identification qPCR Array
  - Glucose stimulated insulin secretion (GSIS) Assay
  - Cytokines profiling
  - Human pancreatic islet treatments and qPCR
  - Western Blotting
  - PKA activity
  - Human fasting mimicking diet
  - Ingredients
  - Supplements
  - Metabolic cages
- **QUANTIFICATION AND STATISTICAL ANALYSIS**

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes six figures and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.cell.2017.01.040. An audio PaperClip is available at http://dx.doi.org/10.1016/j.cell.2017.01.040mmc2.

**AUTHOR CONTRIBUTIONS**

V.D.L conceptualized and supervised the study. C.-W.C, V.V., and R.B. designed and performed experiments, analyzed data, interpreted results, and

REFERENCES

ACKNOWLEDGMENTS

We thank Lora Barsky (USC Flow Cytometry Core Facility) for assistance in the FACS analysis, Michael Sheard (CHLA Fluorescence Activated Cell Sorting Core) for assistance in the cytokines profiling, and Gerrardo Navarrete for preparing the diet. This study was funded in part by NIH/NIA grants AG20642, AG025135, and P01 AG034906 to V.D.L. V.D.L. has equity interest in L-Nutra, a company that develops medical food. All shares will be donated to charitable organizations.

Received: August 11, 2016
Revised: November 23, 2016
Accepted: January 30, 2017
Published: February 23, 2017

REFERENCES


# STAR★METHODS

## KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rabbit anti-glucagon (1:50, IHC)</td>
<td>Abcam</td>
<td>ab8055; RRID: AB_2247265</td>
</tr>
<tr>
<td>Mouse anti-Insulin + Proinsulin (D6C4) (1:500, IHC)</td>
<td>Abcam</td>
<td>ab8304; RRID: AB_2126399</td>
</tr>
<tr>
<td>Rabbit anti-Neurog3 (1:50, IHC)</td>
<td>LSBio</td>
<td>LS-C97692; RRID: AB_2282494</td>
</tr>
<tr>
<td>Rabbit anti-OCT4a (C30A3) (1:50, IHC)</td>
<td>Cell Signaling</td>
<td>2840P; RRID: AB_10841298</td>
</tr>
<tr>
<td>Rabbit anti-OCT4-Chip Grade</td>
<td>Abcam</td>
<td>ab19857; RRID: AB_445175</td>
</tr>
<tr>
<td>Rabbit anti-p70 S6 Kinase (49D7) (1:1000, WB)</td>
<td>Cell Signaling</td>
<td>2708; RRID: AB_390722</td>
</tr>
<tr>
<td>Rabbit anti-phospho p70 S6 Kinase (Thr 389) (108D2) (1:1000, WB)</td>
<td>Cell Signaling</td>
<td>9234; RRID: AB_2269803</td>
</tr>
<tr>
<td>Rabbit anti-PCNA (1:1000, IHC)</td>
<td>Abcam</td>
<td>ab2426; RRID: AB_303062</td>
</tr>
<tr>
<td>Goat anti-PDX1 (1:500, IHC)</td>
<td>Abcam</td>
<td>ab47383; RRID: AB_2162359</td>
</tr>
<tr>
<td>Goat anti-Sox17 (1:100, IHC)</td>
<td>Santa Cruz</td>
<td>sc-17355; RRID: AB_2239898</td>
</tr>
<tr>
<td>Rabbit anti-Sox17 (1:100, IHC)</td>
<td>Millipore</td>
<td>09-038; AB_1587525</td>
</tr>
<tr>
<td>Mouse anti-beta tubulin (AA2) (1:2500, WB)</td>
<td>Millipore</td>
<td>05-661; AB_309885</td>
</tr>
<tr>
<td><strong>Biological Samples</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human serum</td>
<td>Clinical Trial</td>
<td>NCT02158897</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptozocin</td>
<td>Sigma-Aldrich</td>
<td>S0130</td>
</tr>
<tr>
<td>Tamoxifen</td>
<td>Sigma-Aldrich</td>
<td>T5648</td>
</tr>
<tr>
<td>D+ Glucose</td>
<td>Sigma-Aldrich</td>
<td>G7021</td>
</tr>
<tr>
<td>Insulin</td>
<td>Sigma-Aldrich</td>
<td>i6634-50mg</td>
</tr>
<tr>
<td>Collagenase P</td>
<td>Roche Diagnostics Corp</td>
<td>11213857001</td>
</tr>
<tr>
<td>Lipofectamine RNAiMAX Reagent</td>
<td>Thermo Fisher Scientific</td>
<td>13778100</td>
</tr>
<tr>
<td>PKA siRNA</td>
<td>Cell signaling</td>
<td>6574S</td>
</tr>
<tr>
<td>H89</td>
<td>Sigma-Aldrich</td>
<td>B1427</td>
</tr>
<tr>
<td>Rapamycin</td>
<td>LC Laboratories</td>
<td>R-5000</td>
</tr>
<tr>
<td>IG1</td>
<td>ProSpec</td>
<td>CYT-216</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cell Lineage Identification PCR Array (Mouse)</td>
<td>QIAGEN</td>
<td>PAMM-508Z</td>
</tr>
<tr>
<td>Mouse Cytokine 23-plex Assay</td>
<td>BIO RAD</td>
<td>#M60009RDPD</td>
</tr>
<tr>
<td>PKA kinase activity kit</td>
<td>ENZO</td>
<td>ADI-EKS-390A</td>
</tr>
<tr>
<td>Mouse Insulin ELISA</td>
<td>Mercodia</td>
<td>10-1247-01</td>
</tr>
<tr>
<td>Mouse Ultrasensitive Insulin ELISA</td>
<td>ALPCO</td>
<td>80-INMSMU-E01</td>
</tr>
<tr>
<td>Human/Canine/Porcine Insulin Quantikine ELISA Kit</td>
<td>R&amp;D Systems</td>
<td>DINS00</td>
</tr>
<tr>
<td>RNeasy Mini kit</td>
<td>QIAGEN</td>
<td>74104</td>
</tr>
<tr>
<td><strong>Experimental Models: Cell Lines</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Human Pancreatic Type 1 Langerhans Cells</td>
<td>Celprogen</td>
<td>35001-03</td>
</tr>
<tr>
<td>Human Pancreatic Islets of Langerhans Cell</td>
<td>Celprogen</td>
<td>35002-04</td>
</tr>
<tr>
<td><strong>Experimental Models: Organisms/Strains</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse: C57BL/6J</td>
<td>The Jackson Laboratory</td>
<td>JAX: 000664</td>
</tr>
<tr>
<td>Mouse:BKS.Cg-+Leprdb/+Leprdb/Jcl(db/db)</td>
<td>The Jackson Laboratory</td>
<td>JAX: 000642</td>
</tr>
<tr>
<td>Mouse: Ngn3-CreER</td>
<td>Doug Melton Laboratory</td>
<td>N/A</td>
</tr>
</tbody>
</table>

(Continued on next page)
Continued

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse: B6.Cg-Gt(Rosa)26Sor^tm14(CAG-tdTomato)Hze/J</td>
<td>The Jackson Laboratory</td>
<td>JAX: 007914</td>
</tr>
<tr>
<td>Mouse: B6;129-Gt(Rosa)26Sor^tm1D TAM86/J</td>
<td>The Jackson Laboratory</td>
<td>JAX: 010527</td>
</tr>
</tbody>
</table>

Sequence-Based Reagents

| Primer: Ngn3 Forward 5'- GAGAGACTGA-3' | PrimerBank | 296040473c1 |
| Primer: Ngn3 Reverse 5' - GAGGTTGTCATTG GATTGGG-3' | PrimerBank | 296040473c1 |
| Primer: Sox2 Forward 5' - TACAGCATGTCTTA CTCGAC-3' | PrimerBank | 32561854c3 |
| Primer: Sox2 Reverse 5' - GAGGAAGAGGTAA CACACGGG - 3' | PrimerBank | 32561854c3 |
| Primer: Insulin Forward 5'- AGGCTTCTTTGTA CACACCAGG - 3' | PrimerQuest, IDT | N/A |
| Primer: Insulin Reverse 5'- CACACTGCCAC GCTTCTG - 3' | PrimerQuest, IDT | N/A |
| Primer: 18S Forward 5'- AAATCAGTTATCC AAGCTCCTTGC - 3' | PrimerQuest, IDT | N/A |
| Primer: 18S Reverse 5'- GCTAGATTACC ACACCCAGG - 3' | PrimerQuest, IDT | N/A |

Software and Algorithms

<table>
<thead>
<tr>
<th>Software and Algorithms</th>
<th>Source</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>ImageJ</td>
<td>NIH</td>
<td><a href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</a></td>
</tr>
<tr>
<td>ZEN Imaging software (confocal imaging, 3D, Z stack)</td>
<td>Carl Zeiss</td>
<td><a href="https://www.zeiss.com">https://www.zeiss.com</a></td>
</tr>
<tr>
<td>Prism</td>
<td>Graphpad</td>
<td><a href="https://www.graphpad.com">https://www.graphpad.com</a></td>
</tr>
<tr>
<td>Sigmaplot</td>
<td>Systat Software</td>
<td><a href="https://systatsoftware.com/products/sigmaplot/">https://systatsoftware.com/products/sigmaplot/</a></td>
</tr>
</tbody>
</table>

Other:

| Mouse diet: Fasting mimicking diet (FMD) | This study (Table S2) | N/A |

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Valter D. Longo (vlongo@usc.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Mouse models

All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Southern California (USC). All mice were maintained in a pathogen-free environment and housed in clear shoebox cages in groups of five animals per cage with constant temperature and humidity and 12 hr/12 hr light/dark cycle. Prior to supplying the FMD diet, animals were transferred into fresh cages to avoid feeding on residual chow and coprophagy. All animals had access to water at all times. Unless otherwise on experimental diets, mice were fed ad libitum with regular chow (e.g., AIN93G).

**T1D**

High-dose streptozotocin (STZ) injection (150 mg/kg) for inducing T1D was performed to cause β-cell depletion (>70% loss) and hyperglycemia (>250 dl/ml) (Wu and Huan, 2008). Male C57Bl6 mice (16 weeks, n = 18) were weighed and fasted 4 to 6 hr prior to STZ injection. Briefly, STZ was dissolved in sodium citrate buffer (pH 4.5, freshly prepared) at a concentration of 10 mg/ml immediately prior to use and STZ solution was administered intraperitoneally (IP) within 5 min from preparation according to mouse weight. An equal volume of citrate buffer was injected into male and female C57Bl6 mice (4- to 8-months-old, n = 18) that were used as healthy controls. Mice were returned to their cage and food was replaced and 10% sucrose water was provided to prevent hypoglycemia in the days immediately following STZ injection.
Ten-week-old male BKS.Cg-\textsuperscript{-}\textit{Lepr}\textsuperscript{db}/\textit{Lepr}\textsuperscript{db}/Jcl (\textit{db/db}) mice and BKS.Cg-\textsuperscript{+}/\textit{m}/Jcl (\textit{m/m}) control mice (n = 15 for \textit{db/db} and n = 7 for control) were purchased from The Jackson Laboratory. Age-matched wild-type littermates were used as the healthy controls. Unless otherwise specified, mice were not fasted at the time of tissue collection. All experiments and procedures were performed according to an approved protocol by the Institutional Animal Care and Use Committee at University of Southern California.

**Lineage tracing and Lineage ablation**

Hemizygous transgenic Ngn3-CreER mice were bred with R26R\textsuperscript{CAG-LSL-tdTomato} reporter mice for lineage tracing experiments, or bred with R26R\textsuperscript{DTA} mice for lineage ablation experiments (Jackson Laboratory). Tamoxifen (TAM) injections were performed as previously described (Madisen et al., 2010). Briefly, 75 mg/kg TAM was injected i.p. at the interested time points (as indicated in Figure 5B and Figure 5F). Both sex mice (12-16 weeks old) were used n = 6 for each group, n = 3 for vehicle control.

**Human pancreatic islets**

Human Pancreatic Type 1 Langerhans Cells (#35001-03) and non-diabetic control (#35002-04) were purchased from a commercial source Celprogen (Torrance, CA). The cells were seeded at 80% of confluence and cultured with standard medium: Celprogen, M35002-04S for healthy islets and M35001-03S for T1D islets. The cells were plated at 10\textsuperscript{5} per ml density and incubated in the appropriate size flask at 37°C in a 5% CO\textsubscript{2} humidified incubator. Medium were changed every 48h. When reached 65%–75% of confluence, cells were passaged with Celprogen Trypsin-EDTA (T1509-014) and subcultured for expansion.

**Human subjects (FMD)**

Study subjects were recruited under protocols approved by the IRB (approval # HS-12-00391) of the University of Southern California (USC) based on established inclusion and exclusion criteria. Informed consent was obtained from all subjects. Examination and tests included, but were not limited to, blood draws through venipuncture before (AL) and after 5-8 days after completion of the 3\textsuperscript{rd} dietary intervention cycle (RF). Presented are preliminary results for a set of 6 to 8 healthy subjects (see Table S1 for the profiles of these individuals).

**Criteria for inclusion of human subjects**

Generally healthy adult volunteers, subjects of 18-70 years of age, body mass index: 18.5 and up, ability and willingness to provide written informed consent, ability and willingness to undergo multiple cycles of a 5-day dietary regimen, ability and willingness to provide blood samples via venipuncture.

**Exclusion criteria**

Any major medical condition and chronic diseases, mental illness including severe depression and dementia, drug dependency, hormone replacement therapy (DHEA, estrogen, thyroid, testosterone), severe hypertension (systolic BP > 200 mm Hg and/or diastolic BP > 105 mm Hg), underweight (BMI < 18.5 kg/m\textsuperscript{2}), females who are pregnant or nursing, special dietary requirements incompatible with the study interventions or food allergies, alcohol dependency).

**Profile**

Subjects in this study are at age 49.1 ± 6.9, with heights of 166.7 ± 4.7cm, with body weights of 63.32 ± 4.8 kg at baseline and 61.36 ± 4.3 at the end of FMD.

**METHOD DETAILS**

**Mouse fasting mimicking diet**

The mouse version of the FMD is a 4-day regimen using ingredients similar to those used for the human FMD (see Table S2) (Brandhorst et al., 2015). All diet ingredients were thoroughly mixed and then blended together with heated hydrogel (ClearH\textsubscript{2}O, Maine). Mice on the FMD diet were fed 50% of the standard daily calorie intake on day 1 and 10% of normal daily calorie intake on days 2 to 4. All mice were supplied with fresh food during the morning hours (8am-10am). FMD mice generally consumed the supplied food within the first few hours of the light cycle. Control-fed animals usually consumed the supplied food during the dark hours.

**Post-FMD refeeding**

After the end of the day 2-4 diet, mice were fed ad libitum regular chow for up to 10 days to regain body weight before the next FMD cycle.

**Blood glucose and insulin measurement**

Unless otherwise specified, mice were fasted for 6 hr (morning fasting) before blood glucose measurements. Blood glucose was measured through tail vein bleeding with the use of the OneTouch UltraMini Blood Glucose Monitoring System (Lifescan, Milpitas, CA, USA). Plasma insulin levels were determined by mouse enzyme-linked immunosorbent assay (Mercodia, Winston-Salem, NC, USA), according to manufacturer’ s instructions. Whole blood was withdrawn from the facial vein, and plasma was separated by centrifugation at 14,000 rpm for 3 min in plasma separator tubes with lithium heparin (BD, Franklin Lakes, NJ, USA). Briefly, 10 mL of plasma samples and calibrators were aliquoted in a mouse monoclonal anti-insulin antibody-coated 96-well plate. Working
solution containing peroxidase-conjugated anti-insulin antibody was then added to each well (100 μL per well), and the plate was put under shaking conditions at room temperature (RT) for 2 hr. After six washes with washing buffer, 200 μL of 3,3’,5,5’-Tetramethylbenzidine substrate was added to each well and allowed to incubate for 15 min at RT. The reaction was stopped with 0.5 mol/L H2SO4 and optical density (OD) was read at 450 nm with the use of the Victor3 multilabel plate reader (PerkinElmer, Waltham, MA, USA). A standard curve was drawn by plotting OD450 and insulin concentration of calibrators with the use of Sigmaplot 11 data analysis software (Systat Software Inc, San Jose, CA, USA) and used as reference to extrapolate sample values for insulin concentrations (Milanesi et al., 2012; Villani et al., 2014). The homeostatic model assessment (HOMA) was the method used to quantify insulin resistance (HOMA-IR) and beta-cell function (%B). HOMA-IR was calculated using the following formula: HOMA-IR = (Fasting glucose x Insulin)/ 22.5. HOMA %B was calculated using the following formula: HOMA-B = (20 x Fasting Insulin)/(Fasting Glucose-3.5) % (Matthews, 2001).

**Intraperitoneal glucose tolerance testing (IPGTT) and insulin tolerance testing**

Mice were single-caged and fasted for 4 hr prior to the injections. Glucose (1.5 mg/g) or Insulin (0.75 unit/kg) was injected intraperitoneally. Blood glucose levels were measured at 5, 15, 30, 60, and 90 min after the injection.

**Immunofluorescence Analysis**

Briefly, the pancreatic samples were collected without saline perfusion and immediately processed for paraffin embedding and histology as previously described (Milanesi et al., 2012; Villani et al., 2014). Tissues were fixed in 10% neutral phosphate buffer formalin (Polysciences Inc, Warrington, PA, USA) for 1 hr at 4°C and stored in 70% ethanol overnight at 4°C. Tissues were subsequently dehydrated through graded ethanol, toluene and finally embedded in paraffin (TissuePrep, Fisher Scientific, Pittsburgh, PA, USA). Pancreatic sections (5 μm) were sliced with the use of a Leica RM2235 rotary microtome and dried ON. The following day sections were deparaffinized in Histochoice clearing agent (Sigma-Aldrich) and rehydrated through graded ethanol series (100%, 90%, 70%, 50% and 30%) followed by rinsing in distilled water before use. Heat-mediated antigen retrieval with antigen unmasking solution (H-3300, Vector Laboratories) was performed and sections were blocked with 2% bovine serum albumin (BSA) solution for 30 min at RT. The following primary antibodies were used: anti-insulin (Abcam, ab8304), anti-glucagon (Abcam, ab8055), anti-PCNA (Abcam, ab2426), anti-PDX1 (Abcam, ab47383). Additional antibodies used for developmental markers are Anti-Oct4 antibody - ChIP Grade (Abcam, #ab19857) and anti-Oct-4A (C30A3) rabbit mAb (Cell Signaling, 2840P), Anti-Sox17 (Santa Cruz Biotechnology #sc-17355) and Anti- NGN3 (LifeSpan Biosciences, #LS-C97692). Sections were incubated with primary antibodies in a humidified chamber for 1 hr at RT. After PBS washing, sections were incubated for 30 min at RT with secondary antibodies, respectively, Alexa Fluor 555 donkey anti-mouse immunoglobulin (Ig)G, Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor anti-goat 647 (dilution 1/500). All secondary fluorochrome-conjugated antibodies were purchased from Life Technologies. Sections were mounted with Vectashield mounting medium with 4’,6-diamidino-2-phenylindole (Vector Laboratories, Burlingame, CA, USA). The images of the stained sections were captured using a 10x, 20x or a 40x objective as indicated in figure legends with a Leica AF6000 fluorescence microscope. Double staining for Pdx1+ Glucagon+ cells, Insulin+ Glucagon+ cells and Ngn3-tdTomato+ glucagon+ cells was verified by confocal imaging (Zeiss LSM 710). Numbers of cells or areas of interest were measured from 3-5 mice per group, 6-8 pancreas sections per mouse for 20-30 islets per pancreas section. “Islet area” was measured as previously described (Brereton et al., 2014). Basically, we measure total islet cross-sectional area per 2.5mm2 pancreas section (%). Please also see Figures S2–S4 for the absolute cell counts per islet, the numbers and/or area of islets per pancreas section.

**Pancreatic Islet isolation**

Pancreatic islets were isolated form mice as previously described (Li et al., 2009). In brief, mice were sacrificed by CO2 inhalation and immediately processed for pancreatic perfusion. The pancreas was perfused with 3 mL of collagenase P (Roche Diagnostics Corp, 1-1.5 mg/ml, ca 1,000 U/mL) dissolved in HBSS. The collagenase solution was injected by inserting a 3G1/2-G needle into the common bile duct through the joint site of the hepatic duct under the hepatic duct under a dissecting microscope. After full pancreas distension the tissue was digested by incubation at 37°C for 30 min in a total of 2 mL of digestion solution. Digested tissue was vigorously shaken and subsequently washed twice in HBSS containing CaCl2. Islets were purified using Falcon cell strainers (Fisher Scientific) and hand-picked under a dissecting microscope. Islets were washed with PBS and used to extract total RNA for qPCR analysis (> 40 μm in size) or incubated in HBSS solutions for GSIS assay (average sized between 40 and 70 μm) in a humidified incubator (95% air, 5% CO2) at 37°C.

**Cell Lineage Identification qPCR Array**

Total RNA was extracted from purified islets by column method using the RNeasy Mini kit (QIAGEN, Valencia, CA) according to manufacturer’s instructions and quantified with the Nanodrop system (Thermo Scientific, Waltham, MA). cDNA was obtained from the extracted RNA by retrotranscription with the RT2 First Strand Kit (SA Biosciences, QIAGEN, Valencia, CA) following manufacturer’s instructions. The cDNA of each sample was then added to the RT2 SYBR Green qPCR Master Mix and aliquoted for gene expression analysis on specific arrays for the mouse cell lineage identification (PAMM-508Z, SA Biosciences). Gene analysis, including significant values and fold changes, was performed with the online tool provided by SA Biosciences (http://www.sabiosciences.com/pcracrdataanalysis.php).
Glucose stimulated insulin secretion (GSIS) Assay
Isolated purified islets were incubated in RPMI1640 medium (containing 11 mmol/l glucose and supplemented with 100 µg/ml streptomycin, 100 µg/ml penicillin, 2 mmol/l glutamine and 10% FBS) overnight at 37°C (5% CO₂) and then hand-picked into the following medium for GSIS assay: glucose-starved preparation in HEPES buffer (pH 7.4, containing 125 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl₂ and 1.28 mM CaCl₂, 1 mg/ml BS A) for 45 min and then transferred to the basal glucose conditioned medium (2.5G)(10 islets per well into 500ul assay medium containing 2.5mM glucose) for 60 min. Islets were then washed in glucose starvation medium for 5 min and then transferred to glucose stimulation medium (25G) containing 25mM glucose for 60 min. Medium was collected at the indicated time points (Figure 1K). The GSIS experiment was performed at least three times and in triplicate in 24-well tissue culture plates with 10 equally-sized islets per well. Washes in between treatments were performed under a dissecting microscope to preserve the number of islet throughout the assay.

Cytokine profiling
Mouse cytokine 23-plex immunoassay (BIO-RAD, USA) was used to perform simultaneous quantitative detection of multiple analytes from a single serum sample.

Human pancreatic islet treatments and qPCR
Cells were treated for 36h with: Standard medium: Celprogen, M35002-04S for healthy islets and M35001-03S for T1D islets). STS condition (0.5g/liter of Glucose; 2% FBS), H89 (20uM) (Sigma-Aldrich), Rapamycin (RAPA) (20nM) (LC Laboratories, Woburn, MA, USA), IGF1 (40ng/ml) (ProSpec, East Brunswick, NJ, USA) and PKA siRNA (Cell signaling, 6574S). For PKA silencing, cells were seeded at 80% of confluence, after 24 hours they were transfected for 48h with 100nM PKA siRNA (Cell signaling, 6574S) using Lipofectamine RNAiMAX Reagent (ThermoFisher) according to manufacturer instructions. Total RNA was extracted using RNeasy Mini kit (QIAGEN) according to the manufacturer’s instructions and quantified with the use of the Nanodrop system (Thermo Scientific, Wal- tham, MA, USA). Briefly, 1ug of total RNA was extracted using RNeasy Mini kit and reverse transcribed with SuperScript II Reverse transcriptase (Invitrogen) and the detection of the different transcripts (Ngn3, Sox2, Insulin, and 18S as a reference gene) was carried out using the Kapa sybr fast qPCR kit (KAPA BIOSYSTEMS) according to the instructions of the manufacturer. The expression level was analyzed by quantitative real-time polymerase chain reaction (PCR) on a Roche LightCycler 480II. Gene expression was quantified using the comparative Ct method.

Western Blotting
Total cell lysates were prepared using the M-Per Protein Extraction Reagent (ThermoScientific, Rockford, IL, USA) according to manufacturer instructions. Protein concentration was measured with BCA assay (Thermo Scientific). Equal amounts of protein (60 µg) were heat-denatured in lane marker reducing sample buffer (Thermo Scientific), resolved by SDS-PAGE using Novex 4%–20% Tris-Glycine MiniProtein Gels (Thermo Scientific), and transferred to PVDF membranes (Millipore, Darmstadt, Germany). The blots were blocked in 5% BSA for 1h at room temperature and then incubated overnight at 4°C with primary antibody directed against p70 S6 Kinase and phospho-p70 S6 Kinase(Thr389) (Cell Signaling rabbit mAb #2708, rabbit mAb #9234) and antibody against beta- tubulin (Millipore, #05-661). Peroxidase conjugated IgG (Santa Cruz, CA, USA) was used as secondary antibody. Membrane-bound immune complexes were detected by ultra-sensitive enhanced chemiluminescence system (Thermo Scientific) on a photon-sensitive film (Hyperfilm ECL, GE Healthcare, Milano, Italy). Quantification was performed by densitometric analysis using ImageJ64 software.

PKA activity
PKA activity was measured using the PKA kinase activity kit (Enzo Life Science, Inc., Farmingdale, NY, USA) according to manufacturer instructions.

Human fasting mimicking diet
The human version of the FMD is a propriety formulation belonging to L-Nutra (http://l-nutra.com/prolon/). It is a plant-based diet designed to attain fasting-like effects on the serum levels of IGF-I, IGFBP1, glucose and ketone bodies while providing both macronutrients to minimize the burden of fasting and adverse effects (Brandhorst et al., 2015). Day 1 of the FMD supplies ~4600 kJ (11% protein, 46% fat, 43% carbohydrate), whereas days 2-5 provide ~3000 kJ (9% protein, 44% fat, 47% carbohydrate) per day. The FMD comprises proprietary formulations of vegetable-based soups, energy bars, energy drinks, chip snacks, tea, and a supplement providing high levels of minerals, vitamins and essential fatty acids (Figure S3). All items to be consumed per day were individually boxed to allow the subjects to choose when to eat while avoiding accidentally consuming components of the following day. For the human subjects, a suggested FMD meal plan was provided that distributes the study foods to be consumed as breakfast, lunch, snacks, and dinner. See lists below for ingredients and supplements:

Ingredients
Mushroom Soup: Rice flour, Carrot powder, Dried onion, Champignon mushroom powder, Inulin (chicory fiber), Dried champignon mushroom, Salt, Yeast extract, Potato starch, Olive oil, Dried parsley, Natural flavor.
Vegetable Soup: Rice flour, Dried onion, Inulin (chicory fiber), Dried tomato, Dried carrot, Salt, Dried red pepper, Dried leek, Potato starch, Olive oil, Freeze-dried basil, Spinach powder, Dried parsley, Natural flavor.

Tomato Soup: Rice flour, Dried tomato powder, Dried onion, dried tomato pieces, dried carrot, chicory fiber, potato starch, olive oil, Salt, Yeast extract, Dried basil, Dried parsley, Natural flavor.

Pumpkin Soup: Pumpkin powder, rice flour, inulin (chicory fiber), dried carrot, salt, yeast extract, potato starch, olive oil, dried onion, dried parsley, natural flavor.

Energy Bar: Almond meal, Macadamia nut butter, Honey, Pecan, Coconut, Flaxseed meal, Coconut oil, Vanilla extract, Sea salt.

Kale Crackers: kale, golden flax seeds, sunflower seeds, cashews, Sesame seeds, nutritional yeast, apple cider vinegar, hemp seeds, pumpkin seeds, sea salt, onion powder, dill week, black pepper.

Algal Oil Capsule: Algal oil, Gelatin, Glycerin, Purified water, Turmeric, Annatto extract.

Teas: chamomile, spearmint, or Lemon.

Energy drink: Purified water, natural vegetable glycerin, polysyline.

**Supplements**

Vitamin A (as Beta Carotene), Vitamin C (Ascorbic Acid), Vitamin D (as Cholecalciferol), Vitamin E (as DL-Alpha Tocopherol Acetate), Vitamin K (as Phytonadione), Thiamine (as Thiamine Mononitrate), Riboflavin, Niacin (as Niacinamide), Vitamin B6 (as Pyridoxine HCl), Folic Acid, Vitamin B12 (as Cyanocobalamin), Biotin, Pantothenic Acid (as Calcium-D-Pantothenate), Calcium (as Calcium Carbonate and Tribasic Calcium Phosphate), Iron (as Ferrous Fumarate), Phosphorous (as Tribasic Calcium Phosphate), Iodine (as Potassium Iodine), Magnesium (as Magnesium Oxide), Zinc (Zinc Oxide), Selenium (as Sodium Selenate), Copper (as Cupric Sulfate), Manganese (as Manganese Sulfate), Chromium (as Chromium Picolinate), Molybdenum (as Sodium Molybdate). Proprietary Blend: Beet Root Powder, Spinach Leaf Powder, Tomato Fruit Powder, Carrot Root Powder, Collards Greens Powder, Collards (Kale) Leaf Powder. Other Ingredients: Stearic Acid, Microcrystalline Cellulose, Dicalcium Phosphate, Croscarmellose Sodium, Magnesium Stearate, Silicon Dioxide, Pharmaceutical Glaze.

**Metabolic cages**

Whole-body fat and lean mass was noninvasively measured using LF90 time domain nuclear magnetic resonance scanner (Bruker Optics, Inc). Indirect calorimetric and energy balance parameters including food/ water intake, energy expenditure, respiratory exchange ratio (RER), and physical activity were noninvasively assessed for 10d using metabolic cages (TSE Systems Inc., Chesterfield, MO, USA).

**QUANTIFICATION AND STATISTICAL ANALYSIS**

All experiments reported in Figures 1–4 were repeated at least three independent times and those in Figures 5 and 6 were repeated twice. All samples represent biological replicates. Unless otherwise specified in figure legends, all center values shown in graphs refer to the mean. For statistical significance of the differences between the means of two groups, we used two-tailed Student’s t tests. Statistical significance of differences among multiple groups ($\geq 3$) was calculated by performing ANOVA multiple comparisons of the means for each group. No samples or animals were excluded from analysis, and sample size estimates were not used. Animals were randomly assigned to groups. Studies were not conducted blinded, with the exception of all histological analyses.
Figure S1. Diet: FMD, Related STAR Methods

(A) Metabolic effects of FMD and short-term starvation (STS) on body weights with lean- and fat-mass ratio prior to, after STS or FMD and 3 days after refeeding. (B) Water intake, food intake (kcal/day), Total movement and VCO2/VO2 before, during and after STS and (C) after FMD. (D) Levels of circulating insulin and ketone body (β-HB) in mice on FMD and post-FMD refeeding, comparing to that of mice under prolonged fasting (24, 36 and 60 hr). *p < 0.05, **p < 0.01 and ***p < 0.005, t test.
Figure S2. Effects of FMD in Lepr<sup>db/db</sup> Mice, Related to Figure 1 and STAR Methods
(A) Numbers of indicated cell type per islet, (B) Proliferation frequency of indicated cell type per islet, (C) Body weight and (D) Proliferation frequency and numbers and (E) example image of non-insulin/glucagon producing cells (non-α/β) and Pdx1<sup>+</sup> cells. (F) Levels of circulating insulin during IPGTT. (G) Illustration of pancreatic islet sampling. *p < 0.05, **p < 0.01, ***p < 0.005, one-way ANOVA.
Figure S3. Effects of FMD Cycles on STZ-Treated Mice, Related to Figure 2
(A) body weight, one cycle of FMD (B) Numbers of indicated cell type per islet, (C) Proliferation frequency of indicated cell type per islet, (D) Proliferation frequency of α cells and number of Pdx1+ α cells per islet and (E) Proliferation frequency and numbers of the non-insulin/glucagon producing cells (non-α/β) and (F) Levels of circulating cytokines. *p < 0.05, **p < 0.01, ***p < 0.005, t test.
Figure S4. Effects of FMD and Post-FMD Refeeding on Non-diabetic Wild-Type Mice, Related to Figure 3

(A) Number and area of pancreatic islets per pancreas section. (B) Numbers of indicated cell type per islet. (C) Proportion and (D) number of Proliferation frequency of indicated cell type per islet. (E) Number of Pdx1⁺ transitional cells per islet. (F) Representative images of Pdx1⁺ transitional cells. (G) z stack confocal microscopy images of Gluc⁺ Ins⁺ cells. (H) Proliferation frequency and numbers of the non-insulin/glucagon producing cells (non-α/β) in wild-type mice without STZ treatments. *p < 0.05, **p < 0.01, ***p < 0.005, one-way ANOVA.
Figure S5. Effects of FMD on Expression of Developmental Markers of β-Cell in Adult Mice, Related to Figures 4 and 5

(A) Fold-regulation of genes significantly (*p < 0.05) up- or downregulated by FMD or RF1d comparing to AL. The p values are calculated based on a Student’s t test of the replicate 2 (- ΔCt) values for each gene in the control group and treatment groups. (B) Immunostaining for proteins expression of lineage markers in pancreatic islets. (C) schematic time line and representative images of corn oil (vehicle control) treatments for Ngn3-lineage ablation experiments shown in Figure 5F.
Figure S6. Related to Figure 6
(A) Gene expression and (B) insulin production of healthy pancreatic islets (HI) and T1DI treated with serum form subjects at indicated time points. ****p < 0.0001, t test.